Zoetis Inc. $ZTS Stock Holdings Increased by Moran Wealth Management LLC

Moran Wealth Management LLC raised its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 66.1% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 410,762 shares of the company’s stock after buying an additional 163,458 shares during the period. Zoetis comprises approximately 0.8% of Moran Wealth Management LLC’s investment portfolio, making the stock its 20th biggest position. Moran Wealth Management LLC owned approximately 0.10% of Zoetis worth $29,517,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the business. Prosperity Bancshares Inc acquired a new stake in shares of Zoetis during the 4th quarter valued at $25,000. Cassaday & Co Wealth Management LLC acquired a new position in shares of Zoetis in the 1st quarter worth $28,000. Elyxium Wealth LLC acquired a new stake in shares of Zoetis during the fourth quarter worth $32,000. Root Financial Partners LLC raised its position in shares of Zoetis by 66.5% during the first quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock worth $30,000 after purchasing an additional 103 shares during the period. Finally, Wellington Grp LLC lifted its holdings in shares of Zoetis by 6,675.0% during the first quarter. Wellington Grp LLC now owns 271 shares of the company’s stock valued at $32,000 after purchasing an additional 267 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the company. HSBC decreased their price target on Zoetis from $140.00 to $95.00 and set a “buy” rating for the company in a research report on Monday, July 6th. BNP Paribas Exane cut their price objective on Zoetis from $146.00 to $110.00 and set an “outperform” rating on the stock in a report on Tuesday, August 11th. Piper Sandler reduced their price objective on shares of Zoetis from $90.00 to $80.00 and set a “neutral” rating for the company in a research note on Monday, August 10th. William Blair reiterated a “market perform” rating on shares of Zoetis in a report on Thursday, August 6th. Finally, Citigroup dropped their target price on shares of Zoetis from $112.00 to $96.00 and set a “buy” rating on the stock in a research report on Tuesday, August 11th. Eight analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Zoetis currently has a consensus rating of “Hold” and a consensus price target of $109.62.

Zoetis Stock Performance

Shares of Zoetis stock opened at $73.64 on Friday. Zoetis Inc. has a 12 month low of $71.45 and a 12 month high of $160.48. The company has a quick ratio of 1.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.87. The stock has a market cap of $30.43 billion, a PE ratio of 12.13, a price-to-earnings-growth ratio of 1.28 and a beta of 0.74. The business has a fifty day simple moving average of $76.30 and a 200-day simple moving average of $99.01.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, beating the consensus estimate of $1.85 by $0.02. The firm had revenue of $2.47 billion for the quarter, compared to analyst estimates of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.Zoetis’s quarterly revenue was down .2% on a year-over-year basis. During the same period in the previous year, the firm earned $1.76 earnings per share. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, sell-side analysts anticipate that Zoetis Inc. will post 6.19 EPS for the current fiscal year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be issued a $0.53 dividend. The ex-dividend date is Monday, July 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.9%. Zoetis’s dividend payout ratio is currently 34.93%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.